Viral Suppression among People Living with HIV on Antiretroviral Therapy in N’Djamena: Analysis of 15 Treatment Sites

Résumé fourni par la source

The aim of this study is to contribute to our understanding of HIV viral suppression in patients treated with DTG-based regimens and various other antiretroviral (ARV) regimens, and to identify associated factors. Methods: This is a descriptive cross-sectional study conducted at 15 HIV care sites (PEC) from February to March 2022. Viral loads (VL) in patients on ARV therapy were determined using Generic HIV (Biocentric?) kits and the Xpert HIV-1 Viral Load XC (GeneXpert?) test. Sociodemographic, therapeutic, and virological data were collected using a pre-designed questionnaire. Data processing and analysis were performed using Stata software. Observations with missing data were excluded. The significance level used for the multivariate analysis was 5%. Results: Of the 8852 expected HIV-positive individuals, 3259 (36.8%) had their viral load measured. Female patients were in the majority, with 1468 (98.4%) compared to 24 (1.6%) males. The 31- to 45-year-old age group was the largest compared to other age groups. The highest rates of viral suppression (VC Conclusion: The ARV drug combinations used generally resulted in good viral load suppression. DTG is a good alternative to other ARV drugs in first-line ART.